How Did Novo Nordisk’s NovoMix and Human Insulin Perform in 2017?
In 3Q17, Novo Nordisk’s (NVO) NovoMix reported revenues of 2.4 billion Danish krone (or DKK), which reflected ~1% growth on year-over-year (or YoY) basis.
Jan. 8 2018, Updated 7:33 a.m. ET
NovoMix revenue trends
In 3Q17, Novo Nordisk’s (NVO) NovoMix reported revenues of 2.4 billion Danish krone (or DKK), which reflected ~1% growth on year-over-year (or YoY) basis. In 3Q17, in the US, Europe, AAMEO, China, Japan & Korea, and Latin America, NovoMix generated revenues of 346 million DKK, 452 million DKK, 640 million DKK, 849 million DKK, 104 million DKK, and 28 million DKK, respectively. In 3Q17, in the US, AAMEO, Europe, China, Japan & Korea, and Latin America, NovoMix witnessed an ~11% decline, an 8% decline, a 13% increase, a 9% increase, a 25% decline, and a 36% increase on a YoY basis, respectively.
NovoMix reported revenues for the first nine months of 2017 (or 9M17) 7.8 billion DKK, and ~1% growth on a YoY basis. In the US, Europe, AAMEO, China, Japan & Korea, and Latin America, NovoMix generated 9M17 revenues of 1.3 billion DKK, 1.4 billion DKK, 1.9 billion DKK, 2.7 billion DKK, 338 million DKK, and 83 million DKK, respectively.
Human insulin revenue trends
In 3Q17, Novo Nordisk’s human insulin generated revenues of 2.5 billion DKK, which reflected a ~6% decline on a YoY basis. In 3Q17, in the US, Europe, AAMEO, China, Japan & Korea, and Latin America, human insulin generated revenues of 447 million DKK, 437 million DKK, 532 million DKK, 718 million DKK, 55 million DKK, and 256 million DKK, respectively. In the US, Europe, and AAMEO, in 3Q17, human insulin witnessed a ~11% decline on a YoY basis and a 2% and 18% decline in China and Japan & Korea, respectively.
Human insulin reported 9M17 revenues of 7.6 billion DKK, which reflected a ~5% decline on a YoY basis. In the US, Europe, AAMEO, China, Japan & Korea, and Latin America, human insulin generated 9M17 revenues of 1.3 billion DKK, 1.3 billion DKK, 1.7 billion DKK, 2.4 billion DKK, 175 million DKK, and 649 million DKK, respectively.
In 3Q17, AstraZeneca (AZN), Johnson & Johnson (JNJ), and Novartis (NVS) reported revenues of $6.2 billion, $19.7 billion, and $12.4 billion, respectively. Notably, the Pharmaceutical ETF (PPH) invests ~4.9% of its total portfolio holdings in Novo Nordisk.
